Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

Download: The impact of AMNOG on benefit assessment and market access in Germany

This presentation entitled “The impact of AMNOG on benefit assessment and market access in Germany”  was given at last year’s Market Access USA conference by Dr Michael Kulig, PhD, MPH, Scientific Advisor, Medical Consultancy Department. Download the presentation to learn: AMNOG Overview (G-BA perspective) Current Issues (G-BA perspective) Patient-relevant endpoints Orphan drugs Existing markets Impact of assessments and resolutions Download …

Eisai suspends distribution of Fycompa in Germany over AMNOG disagreement

Eisai has announced that it will temporarily suspend commercial distribution of antiepileptic drug Fycompa following an ongoing disagreement with the German Federal Joint Committee (G-BA) over the value of the drug. Back in March, the G-BA rejected Fycompa, saying that the additional benefit of the drug over GSK and J&J competitors was unproven. But the additional benefit assessment was carried …

Download Ebook: Top AMNOG resolutions for 2013

  AMNOG:  In January 2011, following pressure to reduce annual spending on the German healthcare budget, price controls were introduced in Germany through the AMNOG based pricing system. There is considerable anxiety within the industry as to whether a feasible price will be received in Germany and given the uncertainties, whether effective launch planning is possible. Here we summarise the …